At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 10 enrolled
Drug / intervention
Ad5-hGCC-PADRE vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study of Guanylyl Cyclase C (GCC)-Encoding Replication-Deficient Human Type 5 Recombinant Adenovirus Vaccine (Ad5-hGCC-PADRE) in Stage I and II Colon Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·interventional·Posted Oct 30, 2013·Updated May 2, 2025
In Brief
A Phase 1 clinical trial evaluating Ad5-hGCC-PADRE vaccine for Colon Cancer. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the safety, tolerability and ability to stimulate hGCC-specific antibody and killer T cell immune responses of an Ad5-hGCC-PADRE vaccine in stage I and stage II Caucasian and African American colon cancer patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColon Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedOct 2013
Primary CompletionJun 2014
Study CompletionJan 2016
TodayJul 2026
First PostedOct 30, 2013
Enrollment StartOct 1, 2013
Primary CompletionJun 3, 2014
Study CompletionJan 13, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.7 years ago
Interventions
Ad5-hGCC-PADRE vaccinebiological
A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.